A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Biomarker
- 17 Jan 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 17 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 17 Jan 2017 Status changed from not yet recruiting to recruiting.